In rheumatology, the prior authorization can take longer than the appointment.
Protecting a rheumatology specialty drug claim requires five steps in sequence: verify the benefit and site of service before the drug is ordered, secure authorization that matches the exact drug and dose, document step therapy in payer criteria language, code the J-code to the units administered, and reconcile every infusion against the active authorization. One weak link and the therapy is delayed or the claim is denied. All five done cleanly and the highest-dollar claim in the practice pays on the first pass.
Why does prior authorization matter so much in rheumatology?
Rheumatology revenue does not spread evenly across a schedule. It concentrates. A single biologic infusion can carry more billed value than a full day of office visits. That concentration cuts both directions.
Buy-and-bill sharpens it. The practice purchases the biologic, carries it in inventory, administers it, then bills for it. The money leaves before it arrives. When that claim denies, the acquisition cost is already absorbed. That is not a delayed payment. It is a loss sitting on the books while someone works an appeal.
The administrative load is well documented. In the 2025 AMA Prior Authorization Physician Survey, physicians reported completing an average of 40 prior authorizations per week, with physicians and staff spending 13 hours a week on the process. Of those surveyed, 95 percent reported care delays and 88 percent said prior authorization interferes with continuity of care.
For a specialty built on long-term maintenance therapy, one number matters more than the rest. Among physicians surveyed, 61 percent reported that prior authorization at least sometimes destabilizes a patient who was already stable on a treatment plan. In rheumatology, that is not an administrative inconvenience. It is a clinical setback and a revenue event at the same time.
Recent regulatory relief does not reach this problem. The CMS Interoperability and Prior Authorization final rule requires impacted payers, including Medicare Advantage and Medicaid managed care plans, to decide standard requests within seven calendar days and expedited requests within 72 hours beginning Jan. 1, 2026. Those provisions do not apply to drug authorizations. The therapies rheumatology runs on sit outside the rule.
How does a rheumatology specialty drug claim work?
Every high-dollar rheumatology claim passes through five checkpoints. Each one can stop it.
- Benefit determination. Medical benefit or pharmacy benefit. Buy-and-bill or white bagging. This decision determines who purchases the drug, how it is billed and which fee schedule applies. Get it wrong at intake and the claim is wrong before anyone touches a code.
- Authorization scope. Payers do not authorize a therapy. They authorize a drug, at a dose, for a number of units and administrations, at a specific site of service, across a defined date range. The authorization is a boundary. The claim has to stay inside it.
- Step therapy. Most commercial plans require documented trial and failure of a preferred agent, or a documented contraindication, before covering the prescribed biologic. In the 2025 AMA survey, 75 percent of physicians reported that prior authorization led to patients receiving an initial treatment that was ineffective, often because of step therapy requirements.
- Administration and coding. The J-code must reflect the exact drug and the exact units administered, measured against the HCPCS unit descriptor rather than the vial. Administration codes must match documented infusion start and stop times. Waste must be declared.
- Reconciliation. Every infusion given gets matched back to the authorization on file before the claim goes out, not after the denial comes back.
What documentation do payers require to approve a biologic?
Payers are not persuaded by clinical judgment. They are persuaded by structured evidence that maps to their own coverage criteria.
That means the chart has to carry specific elements. The prior agent, the dates of trial, the response or lack of it, the reason for discontinuation, the disease activity measure, the contraindication with clinical rationale. When those elements live in a narrative note, staff have to hunt for them and payers have room to question them. When they live in a structured template built into the visit, the authorization request writes itself.
This is the difference between practices that approve on first submission and practices that live in peer-to-peer review. The clinical decision is the same. The record is not.
Why do rheumatology infusion claims get denied?
Rheumatology revenue rarely disappears in one dramatic denial. It leaks through small mismatches on very large claims.
Authorization drift. The authorization was obtained for one drug, one dose and one site. Then the dose escalates, the interval shortens, the patient switches agents or the infusion moves to a different location. The clinical change is documented. The authorization is not updated. The claim no longer matches what is on file.
Unit conversion errors. The J-code descriptor unit and the milligrams administered are not the same number. Billing vials instead of descriptor units is one of the most common and most expensive errors in specialty drug billing.
Missing waste modifiers. CMS requires the JW modifier to report discarded amounts and the JZ modifier to attest that nothing was discarded from single-dose containers. Claims for single-dose drugs submitted without either modifier may be returned as unprocessable.
Expired maintenance authorizations. Most plans require annual reauthorization for continuation of therapy. Nothing about the patient changed. The authorization simply lapsed, and the infusion was given anyway.
Infusion time documentation. Initial, sequential and concurrent administration codes depend on documented start and stop times. Missing times mean downcoded or denied administration revenue on top of the drug claim.
Each of these is small on its own. Applied to a panel of recurring infusion patients, they are not.
Rheumatology prior authorization checklist for practice administrators
Before your next infusion week, confirm the following:
- Every scheduled infusion has an active authorization covering the exact drug, dose, units and site of service being administered.
- Step therapy documentation is captured in a structured template at the point of care, not reconstructed later.
- J-code units are calculated against the HCPCS descriptor, not the vial size.
- Every single-dose container claim carries either a JW or a JZ modifier.
- Maintenance patients have reauthorization dates tracked with lead time, not discovered at the chair.
- Infusion start and stop times are documented for every administration.
- Denials are categorized by root cause, so the same failure does not repeat next month.
If your team cannot answer these quickly, the exposure is already on your books.
What disciplined rheumatology billing looks like
The payoff shows up where leaders look. A high-volume rheumatology group partnered with Advantum Health to address rising accounts receivable and limited performance visibility. In 12 months, total accounts receivable fell from $13.5 million to $4.9 million. The 120-day-plus bucket dropped from $6.6 million to $2.1 million. The practice collected more than $31.5 million in total payments.
None of that came from working harder on appeals. It came from structured worklists, root cause denial management and workflows that fit how rheumatology actually bills.
Build the authorization into the visit, not after it
Rheumatology is not harder to bill than other specialties. The claims are simply larger, and the margin for error is smaller.
The practices that keep this revenue moving treat authorization and documentation as clinical workflow, not back-office cleanup. They prove medical necessity in the language payers reward. They track every infusion to the right code and the right unit.
Advantum Health builds revenue cycle operations around the specialties we serve, rheumatology among them. From prior authorization and eligibility verification through coding accuracy and denial management, the work is designed to make the right result repeat.
See how Advantum approaches prior authorization and eligibility verification, and read the full rheumatology case study before your next infusion week.
Frequently asked questions about rheumatology prior authorization
How long does prior authorization take for rheumatology biologics?
Timelines vary by payer and plan type. CMS now requires impacted payers to decide standard requests within seven calendar days and expedited requests within 72 hours, but those timeframes exclude drug authorizations. The American College of Rheumatology reports that coverage delays for rheumatic disease patients can run weeks or months.
What is buy-and-bill in rheumatology?
Buy-and-bill is a model where the practice purchases the biologic, holds it in inventory, administers it in office and bills the medical benefit afterward. The practice carries the acquisition cost until the claim pays. That is why a denied infusion claim is a realized loss rather than a delayed payment.
Why do rheumatology infusion claims get denied?
Most denials trace to five causes: authorization that does not match the drug, dose, units or site administered; step therapy documentation that misses payer criteria; J-code units billed against vial size instead of the HCPCS descriptor; missing JW or JZ modifiers on single-dose containers; and lapsed reauthorization on maintenance patients.
What is the difference between the JW and JZ modifiers?
JW reports a discarded amount from a single-dose container. JZ attests that no amount was discarded. CMS requires one or the other on claims for separately payable Part B drugs from single-dose containers. Claims submitted without either may be returned as unprocessable.
How can a rheumatology practice reduce prior authorization denials?
Build authorization and medical necessity documentation into the clinical visit rather than handling it afterward. Use structured templates that capture payer criteria at the point of care, track reauthorization dates with lead time, reconcile every scheduled infusion against the active authorization before administration, and categorize denials by root cause.